An Open-Label, Multi-Center, Expanded Access Program With Eribulin for the Treatment of Advanced Breast Cancer Refractory.

Trial Profile

An Open-Label, Multi-Center, Expanded Access Program With Eribulin for the Treatment of Advanced Breast Cancer Refractory.

Completed
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 20 Apr 2016

At a glance

  • Drugs Eribulin (Primary)
  • Indications Advanced breast cancer
  • Focus Expanded access; Therapeutic Use
  • Sponsors Eisai Inc
  • Most Recent Events

    • 20 Apr 2016 Results of a retrospective sub-group analysis (n=153) published in the European Journal of Cancer
    • 22 Dec 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 25 Jul 2014 Planned primary completion date changed from 1 Mar 2012 to 1 Mar 2015, as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top